RxDoctor Payments Data

Jeffrey Young, DO

Family Medicine · San Gabriel, CANPI 1376630616

Payments from drug & device makers

$419in general payments, 2019–2025

Across 11 payments — averaging $38.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$161
  • AstraZeneca$151
  • Otsuka America Pharmaceutical, Inc.$30
  • Aimmune Therapeutics, Inc.$29
  • Pfizer$24
  • Merck$23

What the payments were for

  • Food & beverage$31976%
  • Education$10024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$419 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$198,814
Medicare patients
64
Services billed
2,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate45$23,914
CreonLipase/Protease/Amylase16$18,198
VemlidyTenofovir Alafenamide12$17,363
MyrbetriqMirabegron33$14,516
EliquisApixaban20$12,237
MultaqDronedarone Hcl12$9,633
JardianceEmpagliflozin11$6,744
Janumet XrSitagliptin Phos/Metformin Hcl16$6,206
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth48$5,954
Diclofenac Sodium44$4,841
VascepaIcosapent Ethyl12$4,285
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$4,102
Tenofovir Disoproxil Fumarate21$3,922
Pentoxifylline42$1,406
Ibandronate Sodium125$1,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$23$30,12061 claims
Astellas Pharma US IncMyrbetriq$161$14,51633 claims
PfizerEliquis$24$12,23720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in San Gabriel

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →